Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Vykoukal J, Fahrmann JF, Gregg JR, Tang Z, Basourakos S, Irajizad E, et al
Clinical Trials - Key findings Type 2 diabetes (40 weeks): HbA1c 1.241.48% (vs 0.41% placebo) Weight loss 4.57.6% (vs 1.7% placebo) Obesity without diabetes (72 weeks): Mean weight loss 11.2% 54.6% achieved 10% weight loss Improved cardiometabolic markers Efficacy similar to semaglutide/liraglutide (slightly less than tirzepatide) Safety: GI effects most common (during dose escalation) Low discontinuation rates No major hypoglycemia, hepatic, or CV safety signals so far Orforglipron combines oral convenience + GLP-1level efficacy, with the potential to improve access, adherence, and long-term outcomes in diabetes and obesity management
AOD 9604 is typically used by clinics or wellness facilities in biohacking, anti-ageing , or exercise optimization roles
As your body continues treatment, your GLP-1 receptors gradually reduce their sensitivity, meaning the same injection dose produces a smaller appetite-suppressing effect
Not approved for human or veterinary use.
Store Rybelsus in a dry place away from moisture
US$ 26.09
US$ 21.93
US$ 20.47
US$ 21.87
US$ 28.37
US$ 28.11
US$ 27.52
US$ 28.17
US$ 24.62
